Literature DB >> 28477390

Why is colon cancer survival improving by time? A nationwide survival analysis spanning 35 years.

Petur Snaebjornsson1, Larus Jonasson2,3, Elinborg J Olafsdottir4, Nicole C T van Grieken5, Pall H Moller3,6, Asgeir Theodors7, Thorvaldur Jonsson3,6, Gerrit A Meijer1, Jon G Jonasson2,3,4.   

Abstract

There is limited information present to explain temporal improvements in colon cancer survival. This nationwide study investigates the temporal changes in survival over a 35-year period (1970-2004) in Iceland and uses incidence, mortality, surgery rate, stage distribution, lymph node yield, tumor location and histological type to find explanations for these changes. Patients diagnosed with colon cancer in Iceland 1970-2004 were identified (n = 1962). All histopathology was reassessed. Proportions, age-standardized incidence and mortality, relative, cancer-specific and overall survival and conditional survival were calculated. When comparing first and last diagnostic periods (1970-1978 and 1997-2004), 5-year relative survival improved by 12% for men and 9% for women. At the same time surgery rate increased by 12% and the proportion of stage I increased by 9%. Stage-stratified, improved 5-year relative survival was mainly observed in stages II and III and coincided with higher lymph node yields, proportional reduction of stage II cancers and proportional increase of stage III cancers, indicating stage migration between these stages. Improvement in 1-year survival was mainly observed in stages III and IV. Five-year survival improvement for patients living beyond 1 year was minimum to none. There were no changes in histology that coincided with neither increased incidence nor possibly influencing improved survival. Concluding, as a novel finding, 1-year mortality, which previously has been identified as an important variable in explaining international survival differences, is in this study identified as also being important in explaining temporal improvements in colon cancer survival in Iceland.
© 2017 UICC.

Entities:  

Keywords:  1-year survival; colon cancer; epidemiology; population-based; stage migration; survival; time-trend

Mesh:

Year:  2017        PMID: 28477390     DOI: 10.1002/ijc.30766

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  9 in total

1.  Klotho suppresses colorectal cancer through modulation of the unfolded protein response.

Authors:  Tammi Arbel Rubinstein; Shiri Shahmoon; Ehud Zigmond; Tal Etan; Keren Merenbakh-Lamin; Metsada Pasmanik-Chor; Gil Har-Zahav; Iris Barshack; Gilad W Vainer; Nir Skalka; Rina Rosin-Arbesfeld; Chen Varol; Tami Rubinek; Ido Wolf
Journal:  Oncogene       Date:  2018-09-19       Impact factor: 9.867

2.  Colorectal Cancer Prevalence and Survival in Cuenca (Spain).

Authors:  Laura Valiente González; Ricardo de Miguel Ibáñez; Francisco Escribano Sotos
Journal:  J Gastrointest Cancer       Date:  2022-01-13

Review 3.  Oral Tegafur-Uracil Combination plus Leucovorin versus Other Fluoropyrimidine Agents in Colorectal Cancer: A Systematic Review and Meta-Analysis.

Authors:  Satya Pal Kataria; Mukesh Nagar; Shikha Verma; Vinay Purohit
Journal:  South Asian J Cancer       Date:  2022-02-02

4.  Survival Trends After Surgery for Spinal Metastatic Tumors: 20-Year Cancer Center Experience.

Authors:  Robert J Rothrock; Ori Barzilai; Anne S Reiner; Eric Lis; Adam M Schmitt; Daniel S Higginson; Yoshiya Yamada; Mark H Bilsky; Ilya Laufer
Journal:  Neurosurgery       Date:  2021-01-13       Impact factor: 4.654

Review 5.  Klotho and the Treatment of Human Malignancies.

Authors:  Aishani Sachdeva; Jerome Gouge; Christos Kontovounisios; Stella Nikolaou; Alan Ashworth; Kenneth Lim; Irene Chong
Journal:  Cancers (Basel)       Date:  2020-06-23       Impact factor: 6.639

6.  A Modified Tumor-Node-Metastasis Classification for Primary Operable Colorectal Cancer.

Authors:  Chundong Zhang; Zubing Mei; Junpeng Pei; Masanobu Abe; Xiantao Zeng; Qiao Huang; Kazuhiro Nishiyama; Naohiko Akimoto; Koichiro Haruki; Hongmei Nan; Jeffrey A Meyerhardt; Rui Zhang; Xinxiang Li; Shuji Ogino; Tomotaka Ugai
Journal:  JNCI Cancer Spectr       Date:  2020-10-16

7.  Influence of primary tumour and patient factors on survival in patients undergoing curative resection and treatment for liver metastases from colorectal cancer.

Authors:  P Scherman; I Syk; E Holmberg; P Naredi; M Rizell
Journal:  BJS Open       Date:  2019-12-02

Review 8.  Colorectal liver metastases: Current management and future perspectives.

Authors:  Jack Martin; Angelica Petrillo; Elizabeth C Smyth; Nadeem Shaida; Samir Khwaja; H K Cheow; Adam Duckworth; Paula Heister; Raaj Praseedom; Asif Jah; Anita Balakrishnan; Simon Harper; Siong Liau; Vasilis Kosmoliaptsis; Emmanuel Huguet
Journal:  World J Clin Oncol       Date:  2020-10-24

9.  Temporal recalibration for improving prognostic model development and risk predictions in settings where survival is improving over time.

Authors:  Sarah Booth; Richard D Riley; Joie Ensor; Paul C Lambert; Mark J Rutherford
Journal:  Int J Epidemiol       Date:  2020-08-01       Impact factor: 7.196

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.